A preclinical study demonstrated that combining an orally active Gal-3 antagonist with the PD-L1 blockade inhibitor promotes tumor immune infiltration, reduces lung adenocarcinoma growth, and blocks metastasis [63]. Here, CD274 is linked to neoplasm.